Alexion Pharms Inc patent expiration
1. Voydeya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796741 | ALEXION PHARMS INC | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
Dosage: TABLET
More Information on Dosage
VOYDEYA family patents
